PP_1170x120_10-25-21

carfilzomib

FDA approves addition of positive overall survival data to Kyprolis label

FDA approves addition of positive overall survival data to Kyprolis label

THOUSAND OAKS, Calif. — Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 Aspire trial to the U.S. Prescribing Information for Kyprolis (carfilzomib). Data added to the label showed that Kyprolis, lenalidomide and dexamethasone (KRd)

Adheris Health